You are here

SBIR Phase I: Volatile gene expression reporters for use during fermentation

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0912541
Agency Tracking Number: 0912541
Amount: $99,981.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: NSF 08-548
Solicitation Year: N/A
Award Year: 2009
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
7 Tide St Unit 2B
Boston, MA 02210
United States
DUNS: 827811626
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Reshma Shetty
 (877) 422-5362
Business Contact
 Reshma Shetty
Title: DPhil
Phone: (877) 422-5362
Research Institution

This Small Business Innovation Research Phase I project proposes to develop a set of novel, versatile measurement tools for use during fermentation and scale-up in metabolic engineering. The tools will be based on the production of odorants and enable real-time time monitoring of gene expression levels during fermentation. Metabolic engineering holds great promise for enabling a range of important applications including cellulosic biofuels, therapeutics production, and bio-based, environmentally-friendly chemical manufacturing. But any such project requires that an engineered organism expressing the relevant biosynthetic pathway be scaled up from lab-sized cultures to large-scale commercial fermentation. This is not a straightforward task, and is different for every project, because the fermentation conditions required for each engineered strain are different. The new measurement tools will enable more detailed quantification of cell state during fermentation so that strain and pathway optimization is more informed. The broader impacts of this research are to enable more informed strain optimization for large-scale fermentation thereby reducing R&D costs for the bio-based manufacturing industry. With the growing interest in clean technology and alternatives to petroleum-based manufacturing, many new companies and
existing companies are moving into the bioengineering and biomanufacturing industries. However, all of these companies face a common hurdle of scaling up production of their fuel, specialty chemical or biomaterial to commercial scale. The companies spend significant R&D money and time optimizing pathway yield during fermentation. For example, Dupont took 7 years and $400M to scale-up microbial production of 1,3-propanediol. Jay Keasling, a founder of Amyris Biotechnologies, a leading synthetic biology company, reported that Amyris spends 95% of their time trying to find and eliminate unintended interactions between components in their engineered metabolic pathways. Reducing the R&D costs in the biofuels and industrial biotechnology industries would open up new application areas to environmentally-friendly, bio-based production solutions. This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government